We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina (ILMN) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
In its upcoming report, Illumina (ILMN - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.36 per share, reflecting an increase of 1.5% compared to the same period last year. Revenues are forecasted to be $1.14 billion, representing a year-over-year increase of 4.9%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Illumina metrics that Wall Street analysts commonly model and monitor.
According to the collective judgment of analysts, 'Revenue- Product revenue- Total Consumable' should come in at $865.12 million. The estimate indicates a change of +6% from the prior-year quarter.
The consensus estimate for 'Revenue- Service and other revenue' stands at $175.54 million. The estimate indicates a change of +11.8% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Product revenue' at $974.75 million. The estimate indicates a change of +5.2% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- Product revenue- Total Instruments' will likely reach $109.62 million. The estimate indicates a change of -1.2% from the prior-year quarter.
Analysts predict that the 'Revenue- Sequencing- Instruments' will reach $104.01 million. The estimate indicates a year-over-year change of -2.8%.
Based on the collective assessment of analysts, 'Revenue- Sequencing- Consumables' should arrive at $788.98 million. The estimate points to a change of +5.6% from the year-ago quarter.
The consensus among analysts is that 'Revenue- Microarrays- Instruments' will reach $3.43 million. The estimate points to a change of -14.3% from the year-ago quarter.
Analysts forecast 'Revenue- Microarrays- Consumables' to reach $78.71 million. The estimate indicates a change of +14.1% from the prior-year quarter.
It is projected by analysts that the 'Revenue by Source- Total product revenue- Sequencing' will reach $892.99 million. The estimate indicates a year-over-year change of +4.6%.
Illumina shares have witnessed a change of +2.8% in the past month, in contrast to the Zacks S&P 500 composite's -0.2% move. With a Zacks Rank #2 (Buy), ILMN is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Illumina (ILMN) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
In its upcoming report, Illumina (ILMN - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.36 per share, reflecting an increase of 1.5% compared to the same period last year. Revenues are forecasted to be $1.14 billion, representing a year-over-year increase of 4.9%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Illumina metrics that Wall Street analysts commonly model and monitor.
According to the collective judgment of analysts, 'Revenue- Product revenue- Total Consumable' should come in at $865.12 million. The estimate indicates a change of +6% from the prior-year quarter.
The consensus estimate for 'Revenue- Service and other revenue' stands at $175.54 million. The estimate indicates a change of +11.8% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Product revenue' at $974.75 million. The estimate indicates a change of +5.2% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- Product revenue- Total Instruments' will likely reach $109.62 million. The estimate indicates a change of -1.2% from the prior-year quarter.
Analysts predict that the 'Revenue- Sequencing- Instruments' will reach $104.01 million. The estimate indicates a year-over-year change of -2.8%.
Based on the collective assessment of analysts, 'Revenue- Sequencing- Consumables' should arrive at $788.98 million. The estimate points to a change of +5.6% from the year-ago quarter.
The consensus among analysts is that 'Revenue- Microarrays- Instruments' will reach $3.43 million. The estimate points to a change of -14.3% from the year-ago quarter.
Analysts forecast 'Revenue- Microarrays- Consumables' to reach $78.71 million. The estimate indicates a change of +14.1% from the prior-year quarter.
It is projected by analysts that the 'Revenue by Source- Total product revenue- Sequencing' will reach $892.99 million. The estimate indicates a year-over-year change of +4.6%.
View all Key Company Metrics for Illumina here>>>Illumina shares have witnessed a change of +2.8% in the past month, in contrast to the Zacks S&P 500 composite's -0.2% move. With a Zacks Rank #2 (Buy), ILMN is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .